Why RADR Could Be Lantern Pharma's Most Undervalued Asset

Most people look at Lantern Pharma ($LTRN) and see a small biotech with a few oncology programs. What they often miss is RADR. RADR isn't a chatbot. It's an AI-driven oncology platform designed to identify which patients are most likely to respond to specific therapies by analyzing billions of data points across genomics, transcriptomics, drug response datasets, and clinical outcomes. Instead of asking: "Which drug fits this cancer?" RADR asks: "Which patients are most likely to benefit from thi